All In Biotech

Drug Trial Radar · NCT06062069

A Study of CT-868 in Type 1 Diabetes Mellitus

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

111

Actual

Start

Nov 27, 2023

Primary completion

Jul 7, 2025

Study completion Jul 7, 2025

Sponsor

Lead sponsor
Carmot Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.

Conditions

  • Overweight
  • Obese
  • Type 1 Diabetes Mellitus

Interventions

  • CT-868Drug

    CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.

  • CT-868 Pen InjectorDevice

    The CT-868 pen injector is a multi-dose, single-participant, disposable pen.

  • CT-868 Pen Injector, PlaceboDrug

    The placebo pen injector is identical and contains the same ingredients except for CT-868.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16Time frame: Baseline (Day 1) to Week 16

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • John Muir Physician Network Clinical Research Center

    Concord, California

  • Headlands Research- AMCR

    Escondido, California

  • University of Colorado - Barbara Davis Center for Diabetes

    Aurora, Colorado

  • Denver Endocrinology Diabetes and Thyroid Center

    Englewood, Colorado

  • Advent Health

    Orlando, Florida

  • Orlando Health Science Clinic, LLC

    Orlando, Florida

  • Innovative Research Institute

    Port Charlotte, Florida

  • Atlanta Diabetes Associates

    Atlanta, Georgia

  • Rocky Mountain Clinical Research, LLC- Idaho Falls, Idaho

    Idaho Falls, Idaho

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, Iowa

  • MedStar Health Research Institute - Washington Hospital Center

    Hyattsville, Maryland

  • University of North Carolina Health Sciences at MAHEC

    Asheville, North Carolina

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Lucas Research, Inc

    Morehead City, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Texas Diabetes and Endocrinology, P.A

    Austin, Texas

  • Velocity Clinical Research - Dallas

    Dallas, Texas

  • Research Institute of Dallas

    Dallas, Texas

  • Diabetes & Glandular Disease Clinic, P.A.

    San Antonio, Texas

  • Consano Clinical Research

    Shavano Park, Texas

  • Texas Valley Clinical Research, LLC

    Weslaco, Texas

  • Rainier Clinical Research Center

    Renton, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.